Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL262196 | 0.84 | MEN1 (0.53) | KMT2AMEN1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL16963334 | 0.82 | KMT2A (0.55) | KMT2AMEN1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL29158106 | 0.81 | KMT2A (0.50) | KMT2AMEN1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL8566843 | 0.79 | KMT2A (0.49) | KMT2AMEN1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL23361461 | 0.79 | KMT2A (0.49) | KMT2AMEN1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL24937400 | 0.79 | L3MBTL1 (0.56) | KMT2AMEN1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL21617355 | 0.79 | KMT2A (0.60) | KMT2AMEN1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL25457865 | 0.79 | KMT2A (0.49) | KMT2AMEN1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL7948229 | 0.79 | KMT2A (0.60) | KMT2AMEN1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL17452804 | 0.79 | RAB9A (0.50) | KMT2AMEN1ALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4183783-A1 | IMMUNOMODULATOR | Hitgen Inc. (CN) | 2023-05-24 | — | — | EP | disclosed |
| WO-2021027722-A1 | IMMUNOMODULATOR | 成都先导药物开发股份有限公司 | 2021-02-18 | — | — | WO | disclosed |
| US-20160016914-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-21 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| EP-1937264-B1 | COMBINATION THERAPY FOR THE TREATMENT OF URINARY FREQUENCY, URINARY URGENCY AND URINARY INCONTINENCE | MERCK SHARP & DOHME (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016914-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | KMT2A 2302/4885MEN1 363/4885ALDH1A1 1252/4885 |
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | KMT2A 939/4885MEN1 2456/4885ALDH1A1 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.